The anticancer drug tamoxifen is active against Trypanosoma cruzi in vitro but ineffective in the treatment of the acute phase of Chagas disease in mice

AUTOR(ES)

Miguel, Danilo Ciccone, Ferraz, Marcela Lencine, Alves, Rosana de Oliveira, Yokoyama-Yasunaka, Jenicer KU, Torrecilhas, Ana Claudia, Romanha, Alvaro José, Uliana, Silvia RB

FONTE

Memórias do Instituto Oswaldo Cruz

DATA DE PUBLICAÇÃO

2010-11

RESUMO

The activity of the antineoplastic drug tamoxifen was evaluated against Trypanosoma cruzi. In vitro activity was determined against epimastigote, trypomastigote and amastigote forms of CL14, Y and Y benznidazole resistant T. cruzi strains. Regardless of the strain used, the drug was active against all life-cycle stages of the parasite with a half maximal effective concentration ranging from 0.7-17.9 µM. Two experimental models of acute Chagas disease were used to evaluate the in vivo efficacy of treatment with tamoxifen. No differences in parasitemia and mortality were observed between control mock-treated and tamoxifen-treated mice.

Documentos Relacionados

• Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
• Inositol metabolism in Trypanosoma cruzi: potential target for chemotherapy against Chagas' disease
• Incidence of Trypanosoma cruzi transmission through breastfeeding during acute experimental Chagas disease
• Clinical forms of Trypanosoma cruzi infected individuals in the chronic phase of Chagas disease in Puebla, Mexico
• The benefits of using selenium in the treatment of Chagas disease: prevention of right ventricle chamber dilatation and reversion of Trypanosoma cruzi-induced acute and chronic cardiomyopathy in mice